These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34155647)

  • 41. Non-invasive fetal RHD genotyping in the first trimester of pregnancy.
    Cardo L; García BP; Alvarez FV
    Clin Chem Lab Med; 2010 Aug; 48(8):1121-6. PubMed ID: 20482298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Fetal DNA in maternal blood].
    Rijnders RJ; Christiaens GC; de Haas M; van der Schoot CE
    Ned Tijdschr Geneeskd; 2004 Jan; 148(4):170-4. PubMed ID: 14974307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Norwegian experience with nationwide implementation of fetal RHD genotyping and targeted routine antenatal anti-D prophylaxis.
    Sørensen K; Baevre MS; Tomter G; Llohn AH; Hagen KG; Espinosa A; Jacobsen B; Arsenovic MG; Sørvoll IH; Ulvahaug AN; Sundic T; Akkök ÇA
    Transfus Med; 2021 Oct; 31(5):314-321. PubMed ID: 33821537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. No. 343-Routine Non-invasive Prenatal Prediction of Fetal RHD Genotype in Canada: The Time is Here.
    Johnson JA; MacDonald K; Clarke G; Skoll A
    J Obstet Gynaecol Can; 2017 May; 39(5):366-373. PubMed ID: 28454757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. External quality assessment of noninvasive fetal RHD genotyping.
    Clausen FB; Hellberg Å
    Vox Sang; 2020 Jul; 115(5):466-471. PubMed ID: 32166750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn.
    Daniels G; Finning K; Martin P; Soothill P
    Vox Sang; 2004 Nov; 87(4):225-32. PubMed ID: 15585017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
    Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
    Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determination of fetal RHD type in plasma of RhD negative pregnant women.
    Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
    Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care.
    Clausen FB
    Prenat Diagn; 2014 May; 34(5):409-15. PubMed ID: 24431264
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implementation of high-throughput non-invasive prenatal testing for fetal RHD genotype testing in England: Results of a cross-sectional survey of maternity units and expert interviews.
    Ryczek E; White J; Carolan-Rees G
    Transfus Med; 2020 Aug; 30(4):287-294. PubMed ID: 32447792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of RhD status and clinical application of non-invasive prenatal determination of fetal RHD in maternal plasma: a 5 year experience in Cyprus.
    Papasavva T; Martin P; Legler TJ; Liasides M; Anastasiou G; Christofides A; Christodoulou T; Demetriou S; Kerimis P; Kontos C; Leontiades G; Papapetrou D; Patroclos T; Phylaktou M; Zottis N; Karitzie E; Pavlou E; Kountouris P; Veldhuisen B; van der Schoot E; Kleanthous M
    BMC Res Notes; 2016 Apr; 9():198. PubMed ID: 27036548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.
    Müller SP; Bartels I; Stein W; Emons G; Gutensohn K; Köhler M; Legler TJ
    Transfusion; 2008 Nov; 48(11):2292-301. PubMed ID: 18694461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic performance of the noninvasive prenatal FetoGnost RhD assay for the prediction of the fetal RhD blood group status.
    Legler TJ; Lührig S; Korschineck I; Schwartz D
    Arch Gynecol Obstet; 2021 Nov; 304(5):1191-1196. PubMed ID: 33835210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma.
    Grootkerk-Tax MG; Soussan AA; de Haas M; Maaskant-van Wijk PA; van der Schoot CE
    Transfusion; 2006 Dec; 46(12):2142-8. PubMed ID: 17176327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Non invasive fetal RhD genotyping using maternal blood: time for use in all RhD negative pregnant women].
    Carbonne B; Cortey A; Rouillac-Le Sciellour C; Brossard Y
    Gynecol Obstet Fertil; 2008 Feb; 36(2):200-203. PubMed ID: 18243756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Noninvasive fetal RHD genotyping from maternal plasma. Use of a new developed Free DNA Fetal Kit RhD.
    Rouillac-Le Sciellour C; Sérazin V; Brossard Y; Oudin O; Le Van Kim C; Colin Y; Guidicelli Y; Menu M; Cartron JP
    Transfus Clin Biol; 2007 Dec; 14(6):572-7. PubMed ID: 18375165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-invasive foetal RhD genotyping to guide anti-D prophylaxis: an external quality assurance workshop.
    Clausen FB; Barrett AN; Krog GR; Finning K; Dziegiel MH
    Blood Transfus; 2018 Jul; 16(4):359-362. PubMed ID: 28488977
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population.
    Grande M; Ordoñez E; Cirigliano V; Cid J; Grau E; Pericot A; Teixido I; Marin JL; Borrell A
    Prenat Diagn; 2013 Feb; 33(2):173-8. PubMed ID: 23280558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Routine noninvasive prenatal screening for fetal Rh D in maternal plasma-A 2-year experience from a single center in Belgium.
    Blomme S; Nollet F; Rosseel W; Bogaard N; Devos H; Emmerechts J; Cauwelier B
    Transfusion; 2022 May; 62(5):1103-1109. PubMed ID: 35352833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.